BioCentury
ARTICLE | Company News

Management tracks: Zealand taps Alnylam’s Dulac as CEO, plus ICER, Jnana and more

April 5, 2019 10:53 PM UTC

Emmanuel Dulac is leaving his post as chief international strategy officer of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) to become the new CEO of Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL), effective April 22. Dulac succeeds Adam Steensberg, the GI and metabolic disease company’s EVP and chief medical and development officer, who took on the CEO role on an interim basis after Britt Meelby Jensen’s departure in February.

The Institute for Clinical and Economic Review hired Pamela Bradt as CSO. Bradt was CMO at Aegerion Pharmaceuticals Inc., a subsidiary of Novelion Therapeutics Inc. (NASDAQ:NVLN)...